

## Supplement Documents for Results FY2006

### Astellas Pharma Inc.

- Financial Results for FY2006
- Pipeline list

Cautionary statement regarding forward-looking information

*This material includes forward-looking statements based on a number of assumptions and beliefs in light of the information currently available to management and subject to significant risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including adverse economic conditions, currency exchange rate fluctuations, adverse legislative and regulatory developments, delays in new product launches, the pricing and product initiatives of competitors, the inability of the company to market existing and new product effectively, interruptions in production, infringement of the company's intellectual property rights and the adverse outcome of material litigation.*

## Consolidated Results

### 1. Detailed Information from Operating Results

	billion yen, rounded down under 0.1 billion yen				Forecasts			
	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Net Sales	879.3	920.6	41.2	4.7%	477.0	6.5%	968.0	5.1%
Cost of Sales	272.9	284.0	11.0	4.1%				
Ratio of Net Sales	31.0%	30.9%						
Gross Profit	606.3	636.5	30.1	5.0%				
SG&A	413.3	446.0	32.7	7.9%				
Ratio of Net Sales	47.0%	48.4%						
Research and Development	142.0	167.9	25.8	18.2%	70.0	-28.5%	141.0	-16.0%
SG&A excluding R&D	271.2	278.1	6.8	2.5%				
Advertising and Sales Promotion	79.4	77.4	-2.0	-2.5%				
Salaries, Bonuses and Allowances	110.4	117.0	6.6	6.0%				
Other	81.4	83.6	2.2	2.7%				
Operating Income	193.0	190.5	-2.5	-1.3%	125.0	72.5%	250.0	31.2%
Ratio of Net Sales	22.0%	20.7%			26.2%		25.8%	
Non Operating Income	14.8	13.8	-1.0	-6.8%				
Foreign Exchange Gain	3.9	-	-3.9	-				
Non Operating Expenses	5.3	6.5	1.2	23.7%				
Foreign Exchange Loss	-	3.5	3.5	-				
Ordinary Income	202.5	197.8	-4.7	-2.4%	130.0	68.8%	260.0	31.4%
Ratio of Net Sales	23.0%	21.5%			27.3%		26.9%	
Special Gain	7.8	41.0	33.1	421.2%				
Gain on sale of subsidiaries' shares	-	21.2	21.2	-				
Special Loss	33.4	27.1	-6.2	-18.8%				
Merger Costs	21.2	-	-21.2	-				
Expenses for integration and closure of business bases	-	17.6	17.6	-				
Other	12.1	9.4	-2.6	-21.8%				
Income before Income Taxes	177.0	211.7	34.6	19.6%				
Income Taxes	71.7	78.5	6.8	9.6%				
Net Income	103.6	131.2	27.6	26.7%	69.0	13.7%	152.0	15.8%
Ratio of Net Sales	11.8%	14.3%			14.5%		15.7%	

### 2. Segment Information by Business

		billion yen			
		Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)
Sales	Consolidated	879.3	920.6	41.2	4.7%
	Pharmaceutical	869.8	918.5	48.7	5.6%
	Ratio of Net Sales	98.9%	99.8%		
	Rx	847.9	918.5	70.6	8.3%
	Other	9.5	2.0	-7.4	-78.4%
	Ratio of Net Sales	1.1%	0.2%		

OTC business (Zepharm) was sold in April 2006.

### 3. Overseas Sales

		billion yen							
		Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Overseas Sales		398.2	450.0	51.7	13.0%	236.6	10.8%	483.0	7.3%
	Ratio of Net Sales	45.3%	48.9%			49.6%		49.9%	
	North America	191.9	223.2	31.2	16.3%				
	Ratio of Net Sales	21.8%	24.2%						
	Europe	172.2	182.7	10.5	6.1%				
	Ratio of Net Sales	19.6%	19.9%						
	Asia	34.0	44.0	10.0	29.5%				
	Ratio of Net Sales	3.9%	4.8%						

#### 4. Segment Information by Region

billion yen

	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Sales	879.3	920.6	41.2	4.7%	477.0	6.5%	968.0	5.1%
Japan	511.1	501.6	-9.4	-1.9%	254.1	1.2%	509.8	1.6%
Ratio of Net Sales	58.1%	54.5%			53.3%		52.7%	
North America	145.3	173.5	28.2	19.4%	97.5	18.8%	203.5	17.3%
Ratio of Net Sales	16.5%	18.9%			20.4%		21.0%	
Europe	203.2	219.6	16.4	8.1%	111.0	8.3%	224.8	2.3%
Ratio of Net Sales	23.1%	23.9%			23.3%		23.2%	
Asia	19.6	25.7	6.0	30.9%	14.4	17.5%	29.9	16.3%
Ratio of Net Sales	2.2%	2.8%			3.0%		3.1%	
Operating Income	193.0	190.5	-2.5	-1.3%	125.0	72.5%	250.0	31.2%
Japan	138.1	116.6	-21.5	-15.6%				
Ratio of Net Sales	71.6%	61.2%						
North America	32.7	51.5	18.8	57.6%				
Ratio of Net Sales	17.0%	27.1%						
Europe	18.3	23.7	5.3	29.3%				
Ratio of Net Sales	9.5%	12.5%						
Asia	3.8	3.7	-0.0	-2.2%				
Ratio of Net Sales	2.0%	2.0%						
Eliminations	-0.0	-5.2	-5.1					

#### 5. Exchange Rate (Average Rate)

yen

	Mar 06 Full Year	Mar 07 Full Year	Mar 08 1H	Mar 08 Full Year
Yen/USD	113	117	115	115
Yen/EUR	138	150	150	150

#### 6. Per Share Information

	Mar 06 Full Year	Mar 07 Full Year	Mar 08 Full Year
The number of share issued (thousand)	573,949	563,964	
Treasury Stocks (thousand)	15,639	49,593	
The number of share issued after deducting Treasury Stock	558,309	514,371	
Earnings per share (Yen)	183.88	244.07	295.51
Dividend per share (Yen)	70	80	100
Return on Equity (%)	8.8%	11.3%	
Dividend on Earnings (%)	3.3%	3.7%	

## 7. Research and Development Expenses

billion yen

	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Research and Development	142.0	167.9	25.8	18.2%	70.0	-28.5%	141.0	-16.0%
Ratio of Net Sales	16.2%	18.2%			14.7%		14.6%	
Parent	109.2	144.7	35.4	32.4%	62.0	-27.9%	122.0	-15.7%

## 8. Addition to Property, Plant and Equipment

billion yen

	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 Full Year	Change (%)
Addition to Property, Plant and Equipment						
Consolidated	19.6	32.3	12.6	64.3%	30.4	-6.0%
Parent	7.6	19.6	12.0	158.3%	15.4	-21.6%
Depreciation(Tangible)						
Consolidated	27.3	24.2	-3.0	-11.3%	26.6	9.6%
Parent	9.8	8.1	-1.7	-17.4%	9.7	19.2%
Depreciation(Intangible)						
Consolidated	9.9	9.7	-0.1	-1.8%	13.4	37.5%
Parent	4.4	4.4	-0.0	-0.7%	8.5	92.5%

## 9. Employee

	Mar 06 Ending	Mar 07 Ending
Total	15,000	13,900
Japan	8,900	7,900
North America	1,700	1,800
Europe	3,600	3,300
Asia	900	900
Total Medical Representatives	4,800	4,900

## 10. Shareholders

	Mar 06 Ending	Mar 07 Ending
Bank	37.0%	34.7%
Securities	1.6%	2.8%
Other companies	3.5%	3.6%
Foreign companies	47.3%	42.7%
Individuals and others	7.8%	7.4%
Treasury Stock	2.7%	8.8%

## 11.Detailed Pharmaceutical Segment Information

### 1)Consolidated sales of major products

billion yen

	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Prograf	145.9	175.4	29.4	20.2%	92.9	13.4%	190.4	8.6%
Sales by Astellas	140.1	170.1	30.0	21.4%	90.5	14.2%	185.7	9.1%
Japan	14.2	19.0	4.7	33.4%	10.5	13.8%	22.0	15.4%
North America	74.5	88.0	13.4	18.0%	47.1	13.6%	96.7	9.9%
Europe	43.4	52.7	9.3	21.5%	27.5	14.8%	55.5	5.3%
Asia	7.8	10.3	2.4	31.4%	5.4	16.6%	11.4	10.7%
Exports to third parties(Europe)	5.8	5.2	-0.5	-9.4%	2.4	-10.9%	4.7	-11.2%
Harnal	137.8	127.0	-10.8	-7.8%	61.2	0.3%	119.8	-5.7%
Sales by Astellas	100.3	81.4	-18.8	-18.8%	37.0	-9.2%	73.8	-9.4%
Japan	44.9	38.5	-6.3	-14.1%	19.5	0.3%	38.7	0.3%
Europe	49.5	35.3	-14.2	-28.7%	13.4	-23.7%	26.8	-24.2%
Capsule	36.1	18.8	-17.3	-47.9%	5.1	-50.9%	10.1	-46.4%
Omnicon OCAS	13.3	16.4	3.1	23.3%	8.3	16.5%	16.7	1.3%
Asia	5.9	7.5	1.6	28.1%	4.1	10.3%	8.4	10.5%
Bulk and Royalties	37.4	45.5	8.0	21.6%	24.2	19.5%	45.9	0.8%
Vesicare	14.8	36.2	21.4	144.3%	27.3	73.3%	61.5	69.5%
Japan	-	6.2	6.2	-	6.5	99.6%	15.5	149.7%
North America	7.7	17.6	9.9	128.7%	13.0	77.0%	28.9	63.6%
Europe	7.1	12.3	5.2	73.3%	7.7	50.2%	16.6	34.4%
Asia	-	0.0	0.0	-	0.1	740.0%	0.5	848.9%
Funguard/Mycamine	15.2	16.5	1.2	8.2%	9.1	10.4%	18.7	13.3%
Japan	14.0	12.8	-1.2	-8.8%	6.5	-1.3%	12.7	-0.8%
North America	1.2	3.5	2.3	189.3%	2.5	52.2%	5.7	60.6%
Protopic	14.4	14.7	0.2	1.9%	8.8	26.1%	18.1	23.3%
Japan	2.6	2.6	0.0	2.4%	1.5	6.4%	2.8	3.9%
North America	6.5	7.1	0.5	8.6%	4.5	38.7%	9.3	30.2%
Europe	4.9	4.5	-0.4	-8.5%	2.6	18.3%	5.4	20.1%
Asia	0.2	0.3	0.0	9.4%	0.2	35.1%	0.6	77.4%

- Sales of products in Japan are shown in a gross sales basis.

## 2) Consolidated Sales of Other Products

billion yen

Rx Sales in Japan	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Lipitor	91.5	94.7	3.1	3.4%	52.5	10.5%	106.5	12.4%
Gaster	68.8	62.2	-6.5	-9.6%	31.1	-1.3%	61.5	-1.3%
Micardis	37.3	50.3	13.0	34.8%	29.4	23.6%	61.6	22.3%
Cefzon	18.4	14.7	-3.6	-20.1%	6.4	-11.3%	12.7	-13.7%
Myslee	17.1	19.4	2.2	13.4%	11.0	16.3%	22.5	15.9%
Vaccines	14.1	13.3	-0.7	-5.2%	3.0	-37.2%	13.0	-2.8%
Seroquel	15.2	16.8	1.5	10.2%	9.2	9.3%	18.3	8.6%
Frandol	12.7	12.3	-0.4	-3.4%	6.2	-1.7%	12.2	-0.9%
Perdipine	8.9	7.5	-1.4	-16.1%	3.4	-11.0%	6.8	-9.6%
Luvox	10.3	11.1	0.8	7.9%	6.1	7.5%	12.2	9.5%
Dorner	8.5	7.8	-0.6	-8.2%	3.9	-3.8%	7.6	-3.2%
Dogmatyl	7.8	7.3	-0.4	-5.8%	3.7	-2.2%	7.3	-0.9%
Cefamezin	7.5	6.6	-0.8	-11.4%	3.3	-4.7%	6.5	-2.3%
Targocid	7.0	6.4	-0.6	-8.6%	3.2	-6.4%	6.3	-2.7%
Intal	8.4	7.9	-0.4	-5.3%	2.9	-7.4%	6.4	-20.0%
Nivadil	6.7	5.4	-1.2	-18.6%	2.5	-14.5%	4.7	-14.1%
Cibenol	5.1	5.1	0.0	0.3%	2.7	3.0%	5.3	3.4%
Nasea	4.4	4.7	0.3	7.2%	2.6	7.0%	5.2	8.6%
Starsis	4.3	4.3	-0.0	-1.3%	2.2	-1.0%	4.4	1.4%
<b>Total Rx Sales In Japan</b>	<b>440.4</b>	<b>455.2</b>	<b>14.8</b>	<b>3.4%</b>	<b>235.9</b>	<b>4.0%</b>	<b>483.1</b>	<b>6.1%</b>

- Sales of products in Japan are shown in a gross sales basis.

billion yen

RX Sales in North America and EU	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Adenoscan (North America)	35.3	37.1	1.7	4.9%	19.7	7.6%	40.1	8.0%
AmBisome (North America)	8.9	8.8	-0.0	-1.1%	4.5	1.6%	9.4	6.0%
Vaprisol (North America)	0.2	0.1	-0.0	-19.4%	0.4	480.6%	1.0	454.0%
Amevive (North America)	-	2.4	2.4	-	1.4	12.8%	3.1	26.1%
Eligard (Europe)	2.6	5.9	3.2	122.0%	4.4	83.6%	9.8	65.5%

billion yen

Export Sales	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Cefzon Overseas(Exports to third party)	10.9	10.8	-0.1	-1.0%	4.6	-30.0%	4.9	-54.7%
Cefspan Overseas(Exports to third party)	6.0	5.7	-0.2	-4.7%	2.9	-6.8%	5.7	0.0%

## Sales in Europe and North America

Unit:M\$

North America	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Sales	1,282	1,483	200	15.6%	847	19.2%	1,770	19.3%
Prograf	658	752	93	14.3%	410	14.0%	841	11.8%
Adenoscan	312	317	4	1.6%	171	7.9%	349	9.9%
AmBisome	78	75	-3	-4.2%	40	2.0%	82	7.9%
Protopic	57	60	3	5.2%	39	39.1%	81	32.5%
VESIcare	68	150	82	121.5%	113	77.6%	251	66.5%
Mycamine	10	30	19	180.2%	22	52.7%	50	63.4%
Vaprisol	2	1	-0	-22.0%	4	482.5%	9	463.7%
Amevive	-	20	20	-	13	13.2%	27	28.3%

Unit:M€

Europe	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Sales	1,474	1,463	-10	-0.7%	740	5.4%	1,499	2.4%
Harnal	630	538	-92	-14.6%	251	-3.3%	485	-10.0%
Sales by Astellas	359	235	-124	-34.5%	89	-25.8%	179	-24.1%
Capsule	263	126	-136	-52.1%	34	-52.3%	67	-46.4%
OCAS	96	109	12	13.3%	55	13.4%	111	1.4%
Bulk and Royalty	271	303	31	11.7%	161	16.3%	306	0.9%
Prograf	357	386	29	8.2%	199	9.2%	402	3.9%
Sales by Astellas	314	351	36	11.6%	183	11.7%	370	5.4%
Exports to third parties	42	35	-7	-16.7%	16	-13.3%	31	-11.1%
Vesicare	51	82	30	59.2%	52	46.2%	111	34.5%
Protopic	35	30	-5	-16.0%	17	15.1%	36	20.2%
Eligard	19	39	20	103.9%	29	78.7%	65	65.6%

12. Consolidated Balance Sheets

Billion yen

	31-Mar-07		31-Mar-06		Change	Comments
	Amount	Composition	Amount	Composition		
<b>Assets</b>	<b>1,470.7</b>	<b>100.0%</b>	<b>1,584.5</b>	<b>100.0%</b>	<b>-113.8</b>	
<b>Current assets</b>	<b>965.9</b>	<b>65.7%</b>	<b>1,050.3</b>	<b>66.3%</b>	<b>-84.3</b>	
Cash on hand and in banks	223.3		178.1		45.2	
Trade notes and accounts receivable	231.0		227.2		3.8	
Marketable securities	284.3		445.3		-161.0	-- Decrease due to in-licensing activities and share buyback
Inventories	90.9		93.8		-2.8	
Deferred tax assets	58.1		56.0		2.1	
Other	78.5		50.2		28.3	
Allowance for doubtful receivable	-0.5		-0.5		-0.0	
<b>Fixed assets</b>	<b>504.7</b>	<b>34.3%</b>	<b>534.2</b>	<b>33.7%</b>	<b>-29.4</b>	
Property, plant and equipment	<b>194.5</b>	<b>13.2%</b>	<b>206.5</b>	<b>13.0%</b>	<b>-12.0</b>	
Buildings and structures	88.9		99.2		-10.3	
Machinery, equipment and vehicles	30.6		37.2		-6.6	
Tools, furniture and fixtures	22.3		28.3		-5.9	
Land	35.6		35.0		0.6	
Construction in progress	16.7		6.3		10.3	
Other	0.2		0.2		-0.0	
Intangible fixed assets	<b>41.5</b>	<b>2.8%</b>	<b>31.5</b>	<b>2.0%</b>	<b>9.9</b>	
Investments and other assets	<b>268.6</b>	<b>18.3%</b>	<b>296.1</b>	<b>18.7%</b>	<b>-27.4</b>	
Investment securities	210.6		242.1		-31.4	-- Decrease due to sale of stocks and investment securities
Long-term loans receivable	2.2		2.3		-0.1	
Deferred tax assets	37.1		16.4		20.7	
Other	18.6		35.5		-16.8	-- Decrease due to refund of long-term investment
Allowance for doubtful receivables	-0.1		-0.3		0.2	

	31-Mar-07		31-Mar-06		Change	Comments
	Amount	Composition	Amount	Composition		
<b>Liabilities and Shareholders' Equity</b>	<b>1,470.7</b>	<b>100.0%</b>	<b>1,584.5</b>	<b>100.0%</b>	<b>-113.8</b>	
<b>Liabilities</b>	<b>371.7</b>	<b>25.3%</b>	<b>367.1</b>	<b>23.2%</b>	<b>4.5</b>	
<b>Current liabilities</b>	<b>308.8</b>	<b>21.0%</b>	<b>300.2</b>	<b>19.0%</b>	<b>8.6</b>	
Trade notes and accounts payable	73.0		62.5		10.5	
Short-term loans payable	1.6		0.4		1.2	
Other accounts payable	108.8		130.4		-21.5	-- Decrease due to unsestled payment for short term investment
Accrued expenses	65.7		50.8		14.8	
Accrued income taxes	44.3		40.0		4.3	
Accrued consumption taxes	2.0		1.1		0.8	
Allowance for sales rebates and others	4.1		5.8		-1.6	
Other	9.0		9.0		0	
<b>Long-term liabilities</b>	<b>62.8</b>	<b>4.3%</b>	<b>66.9</b>	<b>4.2%</b>	<b>-4.1</b>	
Convertible bonds	-		0.0		0.0	
Long-term loans payable	-		0.5		-0.5	
Deferred tax liabilities	0.5		1.4		-0.8	
Accrued retirement benefits for employees	18.4		40.6		-22.1	-- Decrease due to revision of retirement benefits plan
Accrued retirement benefits for directors	0.0		0.0		-0.0	
Other	43.7		24.2		19.4	-- Increase in payable for in-licensing fees
<b>Shareholders' equity</b>	<b>1,098.9</b>	<b>74.7%</b>	<b>1,217.3</b>	<b>76.8%</b>	<b>-118.3</b>	
Common stock	103.0	7.0%	102.9	6.5%	0.0	
Additional paid-in capital	176.8	12.0%	176.8	11.2%	0.0	
Retained earnings	1,006.6	68.4%	959.2	60.5%	47.4	
Treasury stock	-241.9	-16.4%	-61.9	-3.9%	-179.9	-- Share buyback
Unrealized holding gain on securities	38.0	2.6%	44.2	2.8%	-6.1	
Translation adjustments	15.7	1.1%	-4.3	-0.3%	20.1	
Stock Acquisition Rights	0.2	0.0%	-	0.0%	0.2	
Minority interests	0.3	0.0%	0.4	0.0%	-0.0	

13.Detailed Parent Company Information

P/L

billion yen

	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Sales	576.0	593.7	17.7	3.1%	305.0	3.1%	616.0	3.7%
Cost of Sales	217.5	219.3	1.8	0.9%				
Ratio of Net Sales	37.8%	36.9%						
Gross Profit	358.4	374.3	15.8	4.4%				
SG&A	233.4	267.2	33.7	14.5%				
Ratio of Net Sales	40.5%	45.1%						
Advertising and sales promotion	22.9	25.5	2.5	11.2%				
Reserch and Development	109.2	144.7	35.4	32.4%	62.0	-27.9%	122.0	-15.7%
Salaries, Bonuses and Allowances	59.8	58.1	-1.7	-2.9%				
Other	41.3	38.8	-2.5	-6.1%				
Operating Income	125.0	107.1	-17.8	-14.3%	74.0	86.4%	148.0	38.2%
Ratio of Net Sales	21.7%	18.0%			24.3%		24.0%	
Non Operating Income	37.7	7.3	-30.3	-80.4%				
Non Operating Expenses	3.5	1.9	-1.6	-45.5%				
Ordinary Income	159.2	112.5	-46.6	-29.3%	78.0	79.0%	153.0	35.9%
Ratio of Net Sales	27.6%	19.0%			25.6%		24.8%	
Special Gain	5.6	40.9	35.2	620.9%				
Gain on sale of subsidiaries' shares	-	23.2	23.2	-				
Special Loss	17.2	11.6	-5.5	-32.4%				
Merger Costs	9.8	-	-9.8	-100.0%				
Expenses for integration and closure of business bases	-	5.1	5.1	-				
Other	7.4	6.4	-0.9	-12.5%				
Income before Income Taxes	147.6	141.8	-5.7	-3.9%				
Income Taxes	46.1	47.6	1.4	3.2%				
Net Income	101.4	94.2	-7.2	-7.1%	39.0	-15.6%	87.0	-7.7%
Ratio of Net Sales	17.6%	15.9%			12.8%		14.1%	

Detail of non-consolidated sales

billion yen

	Mar 06 Full Year	Mar 07 Full Year	Change	Change (%)	Mar 08 1H	Change (%)	Mar 08 Full Year	Change (%)
Rx	446.4	461.6	15.1	3.4%	236.2	2.8%	483.4	4.7%
Exporting sales	125.1	132.1	6.9	5.6%	68.8	4.0%	132.6	0.3%
Royalty	32.9	37.3	4.4	13.5%	18.1	4.3%	36.3	-2.9%
Other	4.3	-	-4.3	-100.0%				